Advanced Filters
noise
Found 64,783 clinical trials
T TingBo Liang, MD, PHD

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

This is a phase II open-label, one-arm, multicenter study aimed to explore the efficacy and safety of perioperative (neoadjuvant and adjuvant) treatment for patients with advanced biliary tract carcinoma.

18 - 75 years of age All Phase 2
L Luigi Fontana, MD

The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment

The study aim to evaluate the efficacy of cord blood eye drops in the healing of the damaged corneal epithelium.

18 years of age All Phase N/A

Galunisertib Combined With Capecitabine in Advanced CRC With PM

This is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of capecitabine and galunisertib in patients with colorectal cancer with peritoneal metastases.

18 years of age All Phase 1/2
D Deanna Teoh, MD

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.

18 years of age All Phase 1
R Rebecca E Kotcher, MD

Blue Light as an Anti-inflammatory and Analgesic Strategy in Thoracic Trauma

The main goal of this clinical trial is to learn if light therapy improves pain and inflammation in adults with painful rib fractures. The main question it aims to answer is: Does bright blue light therapy in addition to standard pain treatments improve pain with breathing in adults with painful …

18 years of age All Phase N/A
D David Gomez-Almaguer, MD

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.

18 years of age All Phase 2
F Francesco Ceci

Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer

This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging, in woman affected by Breast Cancer (BC) and referred to diagnostic imaging work-up prior to primary therapy.

18 years of age Female Phase N/A

Arthroscopic Rotator Cuff Repair with UC-MSCs for Large to Massive Tears

Safety Analysis of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients Undergoing Rotator Cuff Repair for Massive or Large Rotator Cuff Tears

19 years of age All Phase N/A
O Oleksii Dobrzhanskyi, MD

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of lymph nodes removed. Secondary study points are the average number of ICG-positive lymph nodes; the average number of metastatic ICG-positive lymph …

18 years of age All Phase 3
F Federica Sancassiani, PsyD, PhD

Non-pharmacological Care for Depression in Cancer Patients Using VR and TMS

Despite its significant impact on individuals and healthcare systems, substantial gaps remain in the clinical and rehabilitative management of depression in oncology patients. Depression in cancer patients is often under-recognized and untreated, and screening tools and structured healthcare pathways are lacking. Even when depression is identified in oncology patients, evidence …

18 - 100 years of age All Phase N/A

Simplify language using AI